← Leaderboards
James F Casella
Johns Hopkins University
$7,723,944
Attributed
$8,480,806
Total exposure
19
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–20$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$12,311,045 · 20
By mechanism
U54$5,067,897 · 3
K12$3,733,713 · 1
R01$1,596,279 · 1
R34$1,052,036 · 1
R21$461,688 · 1
N01$198,758 · 2
Top collaborators
- Emily Barron-Casella2 shared
- Michael Rutledge Debaun2 shared
- Robert J Adams1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Harold P Lehmann$8,009,372
- Robert G Weiss$24,603,173
- Courtney Elaine Gonzalez$170,260
- Jean Lud Cadet$0
- Anne Seymour$77,517
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaResourcesClinical ResearchTransfusionChildhoodInstitutionProgramsUniversitiesStructureLeadershipChildLeadMedicalResearch PersonnelStrokeResearch InfrastructureHuman SubjectRandomizedEpidemiologyAdultBrainAreaCareerClinical Trials
Grant awards (48)
Leveraging Biomarkers of Traumatic Brain Injury in Adults to Assess Cerebral Injury in Children with Sickle Cell Disease$210,795
R21 · FY2020 · HD · contact PI
Leveraging Biomarkers of Traumatic Brain Injury in Adults to Assess Cerebral Injury in Children with Sickle Cell Disease$250,893
R21 · FY2019 · HD · contact PI
Hydroxyurea to Prevent the Central Nervous System Complications of Sickle Cell Disease in Children$163,750
U34 · FY2019 · HL · contact PI
Clinical Hematology Research Career Development Program (K12) at Hopkins$368,777
K12 · FY2016 · HL · contact PI
Clinical Hematology Research Career Development Program (K12) at Hopkins$358,042
K12 · FY2015 · HL · contact PI
Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children$371,888
R34 · FY2014 · HL · contact PI
Clinical Hematology Research Career Development Program (K12) at Hopkins$359,751
K12 · FY2014 · HL · contact PI
Clinical Hematology Research Career Development Program (K12) at Hopkins$323,776
K12 · FY2013 · HL · contact PI
Clinical Hematology Research Career Development Program (K12) at Hopkins$377,304
K12 · FY2012 · HL · contact PI
Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children$313,606
R34 · FY2012 · HL · contact PI
Comprehensive Sickle Cell Center at JHU and UAB$1,220,291
U54 · FY2011 · HL · contact PI
Longitudinal SIT Trial Plasma Proteomic Biomarker Discovery and Validation in SCI$397,909
R01 · FY2011 · HL · contact PI
Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children$366,542
R34 · FY2011 · HL · contact PI
Administrative Core$204,433
U54 · FY2011 · HL · contact PI
Sickle cell scholar component$170,457
U54 · FY2011 · HL · contact PI
Longitudinal SIT Trial Plasma Proteomic Biomarker Discovery and Validation in SCI$393,994
R01 · FY2010 · HL · contact PI
Clinical Hematology Research Development Program (K12) at Johns Hopkins$387,526
K12 · FY2010 · HL · contact PI
Pediatric Hydroxyurea Phase III Clinical Trial$29,769
N01 · FY2010 · HL · contact PI
Comprehensive Sickle Cell Center at JHU and UAB$1,389,710
U54 · FY2009 · HL · contact PI
Longitudinal SIT Trial Plasma Proteomic Biomarker Discovery and Validation in SCI$402,138
R01 · FY2009 · HL · contact PI
Clinical Hematology Research Development Program (K12) at Johns Hopkins$388,259
K12 · FY2009 · HL · contact PI
Administrative Core$243,891
U54 · FY2009 · HL · contact PI
Sickle cell scholar component$243,891
U54 · FY2009 · HL · contact PI
Pediatric Hydroxyurea Phase III Clinical Trial$52,757
N01 · FY2009 · HL · contact PI
Basic and Translational Research Program$1,220,238
U54 · FY2008 · HL · contact PI
Longitudinal SIT Trial Plasma Proteomic Biomarker Discovery and Validation in SCI$402,238
R01 · FY2008 · HL · contact PI
Clinical Hematology Research Development Program (K12) at Johns Hopkins$386,889
K12 · FY2008 · HL · contact PI
Administrative Core$212,348
U54 · FY2008 · HL · contact PI
Sickle cell scholar component$162,638
U54 · FY2008 · HL · contact PI
Clinical Hematology Research Development Program (K12) at Johns Hopkins$384,181
K12 · FY2007 · HL · contact PI
BABY HUG$4,088
M01 · FY2007 · RR · contact PI
SILENT CEREBRAL INFARCT MULTI-CENTER CLINICAL TRIAL$789
M01 · FY2007 · RR · contact PI
Clinical Hematology Research Development Program (K12) at Johns Hopkins$399,208
K12 · FY2006 · HL · contact PI
BABY HUG$11,234
M01 · FY2006 · RR · contact PI
SILENT CEREBRAL INFARCT MULTI-CENTER CLINICAL TRIAL$2,740
M01 · FY2006 · RR · contact PI
BABY HUG$10,716
M01 · FY2005 · RR
STROKE PREVENTION TRIAL IN SICKLE CELL ANEMIA (STOP II)$1,246
M01 · FY2005 · RR
Cognitive and Neuroimaging Studies of Children with Sickle Cell Disease$2,977
M01 · FY2004 · RR
Cognitive and Neuroimaging in Studies of Children with$1,567
M01 · FY2004 · RR
Stroke Prevention Trial in Sickle Cell Anemia (STOP II)$1,567
M01 · FY2004 · RR
FLOCOR IN PATIENTS WITH SICKLE CELL DISEASE CRISIS$0
M01 · FY2002 · RR
PHASE III MULTICNTR,DB,PLACEBO CONT STUDY OF CRL 5861 IN SICKLE CELL ANEMIA$0
M01 · FY2002 · RR
FLOCOR IN PATIENTS WITH SICKLE CELL DISEASE CRISIS$0
M01 · FY2001 · RR
PHASE III MULTICNTR,DB,PLACEBO CONT STUDY OF CRL 5861 IN SICKLE CELL ANEMIA$0
M01 · FY2001 · RR
PEDIATRIC HYDROXYUERA PHASE III CLINICAL TRIAL$116,232
N01 · FY2000 · HB
PEDIATRIC HYDROXYUERA PHASE III CLINICAL TRIAL$0
N01 · FY2000 · HB
FLOCOR IN PATIENTS WITH SICKLE CELL DISEASE CRISIS$0
M01 · FY2000 · RR
PHASE III MULTICNTR,DB,PLACEBO CONT STUDY OF CRL 5861 IN SICKLE CELL ANEMIA$0
M01 · FY2000 · RR